Publicador de contenidos

Investigación

SMART

Identifying Severe Malaria with a new Aptamer-based Rapid diagnostic Test

SMART project.jpg
Duración
November 2021-November 2024
Coordinador
Claudio Parolo
Financiadores
Ministerio de Ciencia e Innovación - Agencia Estatal De Investigación. Convocatoria 2020 de PROYECTOS DE I+D+i

In the context of personalized medicine, the SMART project aims at developing a new diagnostic tool able to precisely diagnose malaria at the point of care. Globally malaria is a life -threatening disease, affecting over 200M and killing over 400k people ever year. Although Europe has been declared free of malaria, nowadays is the most imported parasitic disease in Spain, with around 1000 cases per year and with a not negligible mortality rate of 1-3%. This numbers are almost unacceptable taking into account that exist a highly effective treatment (artemisin based combination therapies). Hence, the diagnosis is the key cornerstone of this disease, since a rapid and accurate diagnosis would lead to a prompt initiation of the treatment and consequently to avoid a huge number of deaths. 

In the same lines, at the moment malaria can be precisely diagnosed just using laboratory-based techniques (i.e. microscopic and PCR techniques), which require days, specialized personnel and equipment. In addition, these requirements are scarce in endemic countries and are not totally implemented in Spain, leading to a delay in the treatment initiation since the patients must be transferred to reference units.  Alternatively, the use of antigenic rapid tests do provide a quicker response, but their sensitivity and specificity often lead to false results and are in consequence far from being the gold standard technique. As a result, it is evident the lack of quick and reliable diagnostic devices that could overcome the mentioned weaknesses. 

In response, we plan to develop a test able to combine the bioanalytical performance of laboratory-based tests with the speed and portability of rapid tests. In order to achieve this, we will first conduct a biomarker discovery study on samples obtained from 90 patients (divided into control group, as well as severe and non-severe cases) that attended the Hospital Clinic of Barcelona between 2015 and 2020. This study aims to select new biomarkers that comparing with the standard microscopic techniques, can perform as a reliable tool to diagnose malaria. Then, based on those results, we will develop new aptamer-based electrochemical sensors capable to precisely quantify in under 5 minutes the presence of those biomarkers in undiluted patient samples. Finally, we will incorporate the sensors into a convenient paper-based platform.

This is one of the first attempts to apply these techniques in the malaria field, and will provide the requirements above mentioned to improve the management of the disease, since the develop of the sensor and the platform provides both the portability required for its wide deployment (i.e. any health care facility or pharmacy) as well as a level of automation (thanks to the intrinsic capillarity of paper) that allows the use by non-trained personnel in any facility (e.g., travelers,  airport workers , social institutions). 

We believe that the SMART project has the potential to revolutionize the way we diagnose malaria, and therefore can have a great impact in the whole management of the disease, which would lead to decrease the number of deaths from malaria in Spain (and worldwide) as well as could protect travelers carrying the device with them.

Total funding

181,500 €

Nuestro equipo

Coordinator

ISGlobal Team

Ver más

Otros proyectos

Ver proyectos pasados

MESA

La Alianza Científica para la Erradicación de la Malaria (MESA) tiene como objetivo avanzar en la ciencia de la erradicación de la malaria.

NHEPACHA

Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas

Estudio inmunológico de la vacuna RTS,S

Estudio de correlatos de protección frente a la malaria después de la vacunación con RTS,S/AS01E: Una evaluación inmunológica exhaustiva en el ensayo clínico de Fase III, doble ciego, aleatorizado, multicéntrico con un grupo control

Euroleish.net

Control of Leishmaniasis. From bench to bedside and community

GREPIMER

Grup de recerca en patología importada i malaties emergents i re-emergents

TESEO

Nuevos regímenes de quimioterapia y biomarcadores para la enfermedad de Chagas

ASINTMAL

Unravelling Disease Tolerance and Host Resistance in Afebrile 'P. falciparum' Infections: a Prospective Study in Mozambican Adults

ADAM

Administración masiva y focal de fármacos antimaláricos para avanzar hacia la eliminación de la malaria en Mozambique: acelerando la implementación de programas y políticas

MULTIPLY

MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention

Science4Pandemics

Citizens engagement digital platform for collective intelligence in pandemics

HIDDENVIVAX

Novel organ-on-a-chip technology to study extracellular vesicles-mediated cryptic infections in Plasmodium vivax malaria

MENA Migrant Health

Transforming data collection and surveillance to drive migrant health research, care and policy

SexMal

Social affairs and sex in P. falciparum: implications for malaria elimination

EpiGen

Building Scalable Pathogen Genomic Epidemiology in Ethiopia

MalTransc

Transcriptional regulation of adaptation and developmental decisions in malaria parasites: from epigenetic variation to directed transcriptional responses

GenMoz

P. falciparum genomic intelligence in Mozambique

BOHEMIA

Broad One Health Endectocide-based Malaria Intervention in Africa

RESPONSE

Mechanisms of the transcriptional responses to changes in the environment in the malaria parasite Plasmodium falciparum

VivaxEVTalk

Extracellular Vesicles as Intercellular Communicators and Biomarkers of Cryptic Erythrocytic Infections in Plasmodium vivax malaria

VaMonoS

Unravelling the heterogoneity and function of monocytes in vaccination and immunity to malaria

CLIMSOCTRYPBOL

Insight on climate and social participatory research for integral management of vectorborne zoonosis caused by Trypanosoma cruzi and Leishmania spp. in the Bolivian Gran Chaco.